Fractional mass filtering as a means to assess circulating metabolites in early human clinical studies
- 13 October 2008
- journal article
- research article
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 22 (22) , 3510-3516
Abstract
Recent changes in the regulatory environment have led to a need for new methods to assess circulating human drug metabolites in early clinical studies with respect to their potential toxicological impact. The specific goals of such studies are to determine if the metabolites present in human plasma following administration of a drug candidate also are observed in plasma from the animal studies employed for preclinical toxicological evaluation, and to estimate corresponding exposure margins (animal:human) for the major metabolites. Until recently, the accepted best practice for the characterization of circulating drug metabolites utilized liquid chromatography/tandem mass spectrometry (LC/MS/MS)‐based methodologies, in conjunction with authentic chemical standards, for the detection and quantitative analyses of metabolites predicted from both animal studies and experiments with human liver preparations in vitro . While this approach is satisfactory for anticipated biotransformation products, metabolites that were not expected to circulate in human plasma frequently escape detection. Current accurate mass instruments enable the use of the technique of fractional mass filtering to detect both expected and unexpected metabolites in a rapid, less resource‐intensive and more robust manner. Application of this technology to several clinical development programs at Merck Research Laboratories has demonstrated the value of fractional mass filtering in the assessment of circulating drug metabolites in early clinical trials. Copyright © 2008 John Wiley & Sons, Ltd.Keywords
This publication has 14 references indexed in Scilit:
- Mass defect profiles of biological matrices and the general applicability of mass defect filtering for metabolite detectionRapid Communications in Mass Spectrometry, 2008
- New analytical strategies in studying drug metabolismAnalytical and Bioanalytical Chemistry, 2007
- Analytical strategies for identifying drug metabolitesMass Spectrometry Reviews, 2007
- MS E with mass defect filtering for in vitro and in vivo metabolite identificationRapid Communications in Mass Spectrometry, 2007
- Detection and Characterization of Metabolites in Biological Matrices Using Mass Defect Filtering of Liquid Chromatography/High Resolution Mass Spectrometry DataDrug Metabolism and Disposition, 2006
- Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometryJournal of Mass Spectrometry, 2006
- A software filter to remove interference ions from drug metabolites in accurate mass liquid chromatography/mass spectrometric analysesJournal of Mass Spectrometry, 2003
- Drug Metabolites in Safety TestingToxicology and Applied Pharmacology, 2002
- Plasma-Pooling Methods To Increase Throughput for in Vivo Pharmacokinetic ScreeningJournal of Pharmaceutical Sciences, 1998
- Determination of the Relative Formation and Elimination Clearance of Two Major Carbamazepine Metabolites in Humans: A Comparison Between Traditional and Pooled Sample AnalysisPharmaceutical Research, 1991